98 results about "Lipoprotein" patented technology

Disclosed herein are synthetic nanoparticles, pharmaceutical compositions, kits, or methods for treating and / or preventing cancer. In some embodiments, the synthetic nanoparticles and / or pharmaceutical compositions comprises a pH sensitive liposome, an apolipoprotein, and andrographolide or derivative thereof. In some embodiments, the synthetic nanoparticles are delivered to a subject for treatment of cancer. In some embodiments, the cancer is T-cell lymphoma or B-cell lymphoma.

This invention discloses a low-astringency prickly pear lactic acid bacteria fermented beverage and its application in lowering blood lipids and antioxidation, relating to the fields of microbial application and food fermentation technology. The fermented beverage of this invention uses prickly pear juice as raw material and is prepared by fermentation with *Lactobacillus plantarum* R-21. It can significantly reduce the tannin content of prickly pear juice, improve taste, and increase the polysaccharide content and antioxidant properties of the beverage. In vivo experiments show that it can reduce the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in mouse liver and serum, inhibit fat accumulation and fatty degeneration in liver cells, and enhance the activity of antioxidant enzymes in the liver, demonstrating important application value in lowering blood lipids and antioxidation.

The present invention relates to an adeno-associated virus (AAV) vector comprising in the 5' to 3' direction: a first AAV2 ITR sequence; a CMV enhancer sequence; a chicken β-actin promoter sequence; a nucleic acid sequence encoding an apolipoprotein 2 (APOE2) polypeptide comprising a Christchurch mutation; a polyA sequence; and a second AAV2 ITR sequence.

The invention provides a preparation method of an apple water kefir beverage and application of the apple water kefir beverage in lowering cholesterol. The method comprises the following steps: preparing apple juice, activating water kefir grains, inoculating the activated water kefir grains into the apple juice, and fermenting to prepare the apple water kefir beverage. The volatile component change in the fermentation process is analyzed through GC-MS and GC-IMS systems, it is proved that the unique bouquet characteristic and flavor coordination of the apple water kefir beverage are improved through water kefir grain fermentation, and meanwhile the organic acid composition is optimized. A mouse model verifies that the apple water kefir beverage has the effect of reducing cholesterol, can reduce liver lipid droplets, total cholesterol, low-density lipoprotein and triglyceride levels, and also can regulate intestinal microbial communities (increase firmicobacteria, bacteroides and faecalis bacteria). The apple water kefir beverage disclosed by the invention has wide market potential and provides a scientific basis for the development of functional beverages.

Provided herein are engineered T cell receptor (TCR) proteins, nucleic acids, vectors, host cells, methods of treating atherosclerosis-related autoimmune disease, and chimeric antigen receptor expressing T cell (CAR-T) comprising a beta chain CDR3 selected from the amino acid sequence of SEQ ID NOS: 179 to 356 and an alpha chain, wherein the TCR is specific for a human apolipoprotein B (ApoB) epitope, antigen-MHC binding portions, and full-length versions of the same.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The invention provides a papillary thyroid carcinoma neck lymph node metastasis risk prediction method and system based on blood indexes and TI-RADS grading, and relates to the technical field of medical data analysis. According to the method, an original data set is constructed by obtaining TI-RADS classification, the maximum diameter of nodules, the number of nodules, gender, age and conventional hematology indexes including apolipoprotein B and carcino-embryonic antigen of a patient, characteristic variables are screened by adopting LASSO regression, and an independent prediction risk factor model is established in combination with multi-factor Logistic regression. And further constructing a column graph model, carrying out performance verification through multiple statistical indexes, and deploying the model to a webpage calculator based on a shiyapp to realize convenient output of the individualized risk probability. According to the method, efficient and accurate prediction of the preoperative lymph node metastasis risk is realized, and reliable decision support can be provided for clinic.

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid (RP) and one or more sequences of micro-interfering ribonucleic acid (miRNA). When the RP interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an apolipoprotein.

The invention discloses application of knockout or inhibition of intestinal epithelium Ufbp1 gene expression in preparation of medicines for preventing and / or treating obesity, and belongs to the technical field of biological medicines. In order to solve the problems of limited effect, many side effects and the like of the existing obesity treatment means, the invention provides Ufbp1 specifically expressed by intestinal epithelial cells as a new anti-obesity intervention target for the first time. By knocking out or inhibiting intestinal epithelium Ufbp1, weight gain, adipose tissue accumulation, hyperlipidemia, liver fatty degeneration and insulin resistance induced by high fat diet can be effectively resisted. The action mechanism is related to influence on secretion of intestinal apolipoprotein ApoB48 / ApoA1 and further regulation and control of whole body lipid metabolism. The invention provides a clear target and theoretical basis for developing novel anti-obesity therapies such as small-molecule inhibitors and nucleic acid drugs of targeted intestinal epithelium Ufbp1, and has important clinical transformation prospects.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

The present invention relates to a composition comprising a complex extract of Coptis japonica, Phellodendron Chinensis, Scutellaria baicalensis, Gardenia jasminoides, and Rheum palmatum. The composition was confirmed to: reduce the levels of blood cholesterol, blood lipids, and blood LDL-cholesterol in patients with dyslipidemia; reduce systolic blood pressure without affecting diastolic blood pressure and pulse rate in patients with hypertension; reduce the level of pulse wave velocity (PWV), which is an indicator of arteriosclerosis, in patients with atherosclerosis, and inhibit the recurrence rate for up to 5 years in patients with cerebral infarction. Accordingly, the composition is provided as a therapeutic agent for dyslipidemia, hypertension, arteriosclerosis, or cerebral infarction. In particular, the composition is made into an encapsulated form rather than conventional decoctions, to reduce the content of geniposide, which is reported as a side effect component, and thus an optimal composition which maintains efficacy against dyslipidemia and does not cause side effects is provided.

The invention provides a lipid nanoparticle and application thereof, and particularly provides a cholesterol-free LNP delivery system based on sterol ionizable lipid. According to the system, a sterol group is integrated into an ionizable lipid skeleton as a hydrophobic tail through molecular design to form a novel sterol ionizable lipid, and the novel sterol ionizable lipid is self-assembled with an auxiliary lipid and a PEG-lipid to form a stable three-component LNP. The problem of high liver enrichment caused by the fact that traditional four-component LNP depends on cholesterol is solved, the affinity of core lipid and apolipoprotein E is remarkably reduced, and an ApoE / LDLR-mediated liver cell uptake way is effectively avoided. Under the condition that cholesterol is completely not needed, the LNP achieves high encapsulation efficiency and excellent stability on mRNA at the same time, liver enrichment is greatly reduced, the targeting performance on extrahepatic tissues such as the spleen is improved, high transfection efficiency and good biocompatibility are achieved, and an innovative platform is provided for delivery of extrahepatic disease RNA drugs.

The invention belongs to the technical field of foods, health-care foods and medicines, and particularly relates to a low-triester and low-sterol egg yolk phospholipoprotein composition and a preparation method thereof. The invention provides a low-triester and low-sterol egg yolk phospholipoprotein composition. The content of egg yolk phospholipids is greater than or equal to 40%. Furthermore, the content of the protein is 50%-60%. Correspondingly, the invention also provides a preparation method of the low-triester and low-sterol egg yolk phospholipoprotein composition, and the preparation method comprises the following steps: preparing the egg yolk phospholipoprotein composition by taking egg yolk powder as a raw material and adopting a supercritical CO2 extraction method; the supercritical CO2 extraction method comprises gradient boosting extraction; an entrainer is adopted in the gradient boosting extraction. According to the method, the extraction pressure is only 15-30 MPa, the CO2 flow rate is 20-30 kg / h, and the extraction pressure and the CO2 flow rate are far lower than those in the prior art, so that the overall energy consumption is reduced, and the operation cost is remarkably reduced; and efficient removal of TG and cholesterol is realized.

The application discloses a kind of methods for constructing electrochemical immunosensor for detecting apolipoprotein A4, comprising: (1) nitrogen-doped graphene and polyethyleneimine are fully stirred in solvent Composite, then add bipyridine functionalized covalent organic framework material and fully stir Composite, obtain NG-PEI-COF composite material;With bipyridine functionalized covalent organic framework material as carrier, gold nanoparticles, apolipoprotein A4 antibody and toluidine blue are loaded in sequence, to obtain tracer probe;(2) on electrode NG-PEI-COF composite material, gold nanoparticles, apolipoprotein A4 and tracer probe are modified in sequence, to obtain the electrochemical immunosensor of the application.The electrochemical immunosensor constructed by the method shows excellent detection performance for apolipoprotein A4, the marker of depression, good reproducibility and stability, and shows good anti-interference performance for a variety of other markers of depression, can be accurately determined in 0.01~300 ng / mL linear range, detection limit is as low as 2.16 pg / mL, and can be applied to serum sample.

The invention relates to the technical field of anti-tumor bionic nanomaterials, and discloses a preparation method and application of tumor-bacterial membrane chimeric nanoparticles, and the preparation method comprises the following steps: carrying out rotary evaporation on dimyristoyl phosphatidylcholine and cholesterol oleate to obtain an HDL rotary evaporation film; mixing the tumor cell membrane with the bacterial membrane to obtain a tumor-bacterial mixed membrane; pre-mixing apolipoprotein ApoA-1 with the tumor-bacteria mixed membrane, and adding the mixed solution into a container containing an HDL rotary evaporation membrane for hydration and reconstruction to obtain a crude suspension; and carrying out ultrafiltration purification on the crude suspension to obtain the tumor-bacterial membrane chimeric nanoparticles. The tumor cell membrane and the bacterial membrane are co-loaded on the high-density lipoprotein, so that the two membrane components can be co-delivered to the dendritic cells to induce maturation of the dendritic cells, are accumulated in tumors and drainage lymph nodes in vivo, activate CD8 + T cell response and have an inhibition effect on tumor growth.

The invention belongs to the field of food science and microbial engineering, and particularly relates to fusarium venanii protein, low-lipoprotein food as well as a preparation method and application of the fusarium venanii protein and low-lipoprotein food. The invention provides a fusarium venanii TB01 protein with high emulsibility as well as a preparation method and application of the fusarium venanii TB01 protein. According to the method, fusarium venanii TB01 mycelium is adopted as a raw material, composite enzymolysis and ultrasonic treatment are innovatively and sequentially cooperated, and functional modification of a protein structure is achieved while high-content protein (larger than or equal to 82%) is extracted through efficient wall breaking. Tests show that the two key indexes of emulsifying activity and stability of the obtained protein are obviously superior to those of soybean protein, and the emulsifying stability of the obtained protein is superior to that of commercial whey protein. Therefore, the protein obtained by the invention can be used as a high-performance emulsifying ingredient, is used for replacing or partially replacing whey protein or soybean protein, and is applied to food systems such as beverages, plant yoghurt, sauce and the like.

The present application relates to the field of food or medicine, and particularly relates to a kind of food-medicinal Chinese medicine composition and Chinese medicine preparation, preparation method and application.The raw materials of the food-medicinal Chinese medicine composition of the present application include yam, fuling, radix puerariae, medlar, mulberry leaf, hawthorn, cassia, polygonatum and gardenia.The food-medicinal Chinese medicine composition of the present application takes "clearing heat and drying dampness, benefiting qi and nourishing yin, promoting blood circulation to remove meridian obstruction" as the basic principle, adjusts the function of viscera, improves sugar, lipid and protein metabolism, promotes the recovery of the body environment to normal, and fits the basic pathogenesis of the middle and late stage of type 2 diabetes, and has accurate treatment effect.

Provided herein are compositions and methods for modifying the human gene, APOC3. Such compositions and methods may result in the reduction of the protein, apolipoprotein C3 (apoC-III) when administered to a human subject. Compositions and methods provided herein may comprise a CRISPR-associated (Cas) protein or uses thereof. Compositions and methods of the present disclosure may be useful for treatment of APOC3 associated conditions, including persistent chylomicronemia, familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG).

A method comprising the steps of: (a) assessing an expression level of at least one protein, selected from Table 1, 2 or 3 in a sample from a subject, where in the at least one protein may be selected from the list comprising: Beta-Ala-His dipeptidase, Apolipoprotein L1, Methanethiol oxidase, Vitamin K-dependent protein S, von Willebrand factor, Plasminogen, Selenoprotein P, Protein disulfide-isomerase A6 and Inter-alpha-trypsin inhibitor heavy chain H3, and (b) using the expression level to determine whether the subject has endometriosis.

The present invention relates to a method for synthesizing hybrid nanoparticles containing apolipoproteins. Specifically, the present invention relates to a method for synthesizing hybrid nanoparticles containing various functional proteins including apolipoproteins using a spiral microvortex device. By the production method of the present invention, nanoparticles having various biological activities, being small, uniform and stable can be produced.

This invention relates to a novel truncated mutant apolipoprotein E and its calibrators and quality control methods. The amino acid sequence of the truncated mutant apolipoprotein E is shown in SEQ ID. The diluent for the calibrators and quality control methods for detecting the truncated mutant apolipoprotein E includes a preservative, a protein protection composition, a surfactant composition, an ion stabilizer composition, and a buffer solution. The method for preparing the apolipoprotein E mutant includes the following steps: 1. Determining the specific sequence of the truncated mutant; 2. Determining that the mutation site is located at position 78 of wild-type apolipoprotein E; 3. Containing the NdeI site and the mutation sequence; locking the mutation; artificially optimizing the apolipoprotein E nucleotides using E. coli; 4. Extracting the corresponding truncated mutant by electrophoresis; 5. Obtaining the truncated mutant apolipoprotein E through recombination with E. coli. This invention solves the problems of discrepancies between detection results and actual clinical applications, as well as the poor stability of apolipoprotein E calibrators.

This invention relates to the field of biological sample processing technology, and provides a method and apparatus for extracting exosomes from body fluids. The apparatus includes: a liquid-filling tube, with a filter at the opening for filtering body fluid samples, and an exosome capturing agent inside the liquid-filling tube; a cap for sealing the opening of the liquid-filling tube; and a magnetic sleeve, with a magnet built into its sidewall or bottom for accommodating the liquid-filling tube and adsorbing the magnetic components in the exosome capturing agent. The exosome capturing agent is composed of a mixture of magnetic microspheres conjugated with various exosome-specific antibodies. This invention eliminates the need for expensive equipment such as ultracentrifuges, completes extraction within one hour, achieves a recovery rate of 85%, a lipoprotein removal rate of 92%, and effectively protects the integrity of exosomes. It is suitable for rapid detection and home self-testing of various body fluids such as blood and urine.

The present application discloses PLPC-DB, an ultrapurified phospholipoproteomic composition derived from the supernatant of peripheral blood mononuclear cells (PBMCs). It comprises essential phospholipids, bioactive proteins, regulatory peptides, and intercellular signaling factors. The composition exceeds 99% purity through a multi-stage purification process combining high-speed centrifugation and selective ultrafiltration (1-50 kDa), followed by lyophilization. This process ensures structural stability for ≥24 months and inter-batch variability <2%. PLPC-DB supports reproducibility and molecular integrity in research and diagnostic settings. Key components include phosphatidylcholine and phosphatidylserine for membrane stabilization and intracellular signaling; structural and regulatory lipids for membrane biogenesis and immune-relevant components involved in antigen presentation, cytokine modulation, and membrane-associated signaling. These may include structurally defined molecules compatible with immunological evaluation in experimental and non-therapeutic settings. The composition is formulated for bioaccessible delivery via sublingual, endonasal, transdermal, and injectable routes, and is intended exclusively for non-therapeutic use in experimental and translational models.

The invention discloses a natural neutrophil apolipoprotein dimer and a preparation method thereof, and belongs to the technical field of biomolecule preparation and biomedical detection. The problems that the recombinant protein dimer prepared by a genetic engineering recombination technology is low in yield, the structure of the recombinant protein dimer is different from that of natural protein, so that the development of antibodies and the detection effect of related kits are influenced, a method for extracting the recombinant protein dimer from peripheral blood is complicated, raw materials are not easy to obtain, and blood resources are wasted are solved. According to the preparation method disclosed by the invention, a leukocyte filter or a leukocyte layer generated in a component blood preparation process is taken as a raw material, a leukocyte lysis solution is adopted for lysis, and the obtained granulocyte lysis solution is combined with anion exchange and affinity chromatography methods to obtain the natural neutrophil apolipoprotein dimer. The preparation method can be used for preparing the natural neutrophil apolipoprotein dimer in batches, is simple and convenient to operate and high in protein yield, and can realize comprehensive utilization of blood resources and turn waste into wealth.

The application discloses a monoclonal antibody which can specifically recognize only neutrophil apolipoprotein homodimer HNL / HNL and cannot recognize monomer form HNL. The amino acid sequence of the heavy chain variable region of the antibody is shown as SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 5. The monoclonal antibody can realize accurate, simple and rapid quantification of the homodimer form HNL / HNL, promote the wide application of the detection index in the clinic, accurately distinguish bacterial infection and viral infection, and reduce the unreasonable use of antibiotics.

The present disclosure relates to double-stranded ribonucleic acid (dsRNAi) agents and compositions that target the APOE gene, and methods of using such dsRNAi agents and compositions to inhibit expression of the APOE gene and to treat subjects with APOE-associated neurodegenerative diseases or disorders, such as Alzheimer's disease and Parkinson's disease.

Conventionally, it has been necessary to collect blood of a subject and perform biochemical analysis to measure LDL cholesterol and HDL cholesterol. However, in this method, a needle or the like needs to be invasively inserted into the skin of the subject, which causes a psychological or physical burden on the subject. According to the present invention, it is possible to non-invasively estimate cholesterol based on attribute information and / or non-invasive biological information of a predetermined user by generating a cholesterol estimation model by machine learning based on attribute information, non-invasive biological information, and blood examination data acquired from a plurality of subjects in advance.

The present invention provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in cells or subjects, and, in some cases, the amount of proteolipid protein 1 in cells or subjects. [Solution] The present invention provides an oligomeric compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the nucleic acid base sequence of the modified oligonucleotide is at least 85% complementary to equal-length portions of the PLP1 nucleic acid, and the modified oligonucleotide comprises at least one modification selected from modified sugar moieties and modified nucleoside-to-nucleoside bonds. Such compounds, methods, and pharmaceutical compositions are useful for improving at least one symptom or characteristic of leukodystrophy.